CRISPR/Cas9-mediated mutation of<i>PHEX</i>in rabbit recapitulates human X-linked hypophosphatemia (XLH)

Abstract

X-linked hypophosphatemia (XLH) is the most common cause of inheritable rickets, with an incidence of 1/20 000 in humans. Inactivation or mutation of the gene &lt;it&gt;PHEX&lt;/it&gt;, a phosphate-regulating endopeptidase, leads to hypophosphatemia and defective bone mineralization in XLH patients. Presently, there is no adequate animal model for safety assessments of physiotherapies and drug screening for XLH rickets. In this study, an XLH model was generated via &lt;it&gt;PHEX&lt;/it&gt; gene knockout (KO) through coinjection of clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9)/sgRNA mRNA into rabbit zygotes. The typical phenotypes of growth retardation, hypophosphatemia, elevated serum FGF23 and bone mineralization were observed in the &lt;it&gt;PHEX&lt;/it&gt; KO rabbits but not in normal controls. In summary, for the first time, we have successfully obtained &lt;it&gt;PHEX&lt;/it&gt; KO rabbits and recapitulated human XLH using the CRISPR/Cas9 system. This novel XLH rabbit model could be utilized as a drug screening model for XLH prevention and preclinical therapy.